Celadon Pharmaceuticals PLC (GB:CEL) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Celadon Pharmaceuticals PLC, a UK-based company specializing in cannabis-based medicines, has announced the admission of 2,625,000 new ordinary shares to the AIM market, bringing the total number of ordinary shares to 68,845,807. This development could be of interest to investors tracking the expansion of pharmaceutical companies in the burgeoning field of medicinal cannabis. Celadon is known for its focus on chronic pain treatments and is currently involved in a UK clinical trial for cannabis-based products.
For further insights into GB:CEL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue